Development of new generation influenza vaccines
- 5 October 2012
- Vol. 30 (51), 7344-7347
- https://doi.org/10.1016/j.vaccine.2012.09.071
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The gold industry standard for risk and cost of drug and vaccine development revisitedVaccine, 2011
- Phase II failures: 2008–2010Nature Reviews Drug Discovery, 2011
- Phase III and submission failures: 2007–2010Nature Reviews Drug Discovery, 2011
- Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impactsExpert Review of Anti-infective Therapy, 2010
- The need for new vaccinesVaccine, 2009
- The annual impact of seasonal influenza in the US: Measuring disease burden and costsVaccine, 2007
- How can we avoid the productivity gap?Drug Discovery Today, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- The challenge of emerging and re-emerging infectious diseasesNature, 2004
- Vaccine R&D success rates and development timesNature Biotechnology, 1996